<DOC>
	<DOCNO>NCT00981721</DOCNO>
	<brief_summary>This study carry see single multiple dos cediranib handle body ( absorb , broken get rid body ) measuring level drug blood Chinese patient advance solid malignancy . The study also assess tolerability 20 30 mg cediranib Chinese patient tumour responds treatment cediranib .</brief_summary>
	<brief_title>A Study Determine Pharmacokinetics Cediranib Chinese Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Provision inform consent Histological and/or cytological confirm advanced solid malignancy Refractory conventional therapeutic modality , appropriate therapy exist For first question : Patients history poorly control hypertension rest blood pressure &gt; 150/100 mmHg presence absence stable regimen antihypertensive therapy , patient require maximal dos calcium channel blocker stabilize blood pressure . Significant haemorrhage ( &gt; 30 ml/bleeding episode previous 3 month ) , haemoptysis ( &gt; 5 ml fresh blood previous 4 week ) thrombotic event ( include transient ischaemic attack ) previous 12 month Recent ( &lt; 28 day ) major thoracic abdominal surgery prior entry study , surgical incision fully heal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Advanced solid malignancy</keyword>
	<keyword>Advanced solid tumour</keyword>
	<keyword>Advanced cancer</keyword>
	<keyword>Cediranib ( RECENTINâ„¢ , AZD2171 )</keyword>
	<keyword>China</keyword>
	<keyword>PK</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>